Market Size
Global Cell Expansion Market reached US$ 25.76 billion in 2025 and is expected to reach US$ 70.86 billion by 2033, growing at a CAGR of 15.3% during the forecast period 2026-2033.
Cell expansion is the process of culturing isolated cells for multiple generations to achieve the desired number of cells for a regenerative response in a patient. This involves serial passages in closed culture vessels and the use of culture medium to remove metabolites and provide nutrients.
Moreover, cell expansion is a crucial process in Biotechnology and regenerative medicine, aiming to increase the quantity of specific cell types for therapeutic applications. It is essential for developing cell-based therapies, such as stem cells and immune cells, which require large numbers of cells. Cell expansion's significance lies in producing functional cells for cancer immunotherapy, tissue engineering, and regenerative medicine.
Market Scope
| Metrics | Details |
| CAGR | 15.3% |
| Market Size Available for Years | 2024-2032 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Bn) |
| Segments Covered | Product Type, Cell Type, Application, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers & Restraints
Rise in the prevalence of chronic diseases
The global cell expansion market is expanding due to the rise in chronic diseases like cancer, diabetes, and autoimmune disorders. This has led to a demand for advanced therapies like regenerative medicine, cell-based therapies, and personalized treatments. Cell expansion is crucial for developing these treatments, and healthcare providers and researchers are seeking innovative solutions to meet the global need for effective treatment options.
For instance, in 2023, according to Institute for Health Metrics and Evaluation, Diabetes affects over half a billion people globally, affecting men, women, and children of all ages. The number is projected to double to 1.3 billion in the next 30 years, with every country experiencing an increase. The global prevalence rate is 6.1%, making diabetes one of the top 10 leading causes of death and disability. North Africa and the Middle East have the highest rate at 9.3%, which is projected to rise to 16.8% by 2050.
Ethical concern related to cell biology
Ethical concerns in cell biology are limiting the cell expansion market. The use of embryonic stem cells, which involve human embryo destruction, has led to restrictions in many countries. Adult stem cells, an ethical alternative, often involve invasive procedures, raising concerns about patient consent and safety. Genetically modified cells pose potential risks to patients and the environment. These ethical concerns are hindering the growth of the cell expansion market.
Market Segment Analysis
The global cell expansion market is segmented based on product type, cell type, application, end user and region.
The instruments from the product type segment accounted for approximately 41.3% of the cell expansion market share
The instruments from the product type segment accounted for approximately 41.3%. Instruments are crucial in cell expansion, enabling controlled growth and multiplication for therapeutic and research purposes. Automated bioreactors, cell counters, centrifuges, and incubators maintain optimal conditions during cell culture, ensuring consistency, scalability, and efficiency. These devices are essential for regenerative medicine, immunotherapy, and tissue engineering. Advanced instrumentation improves cell viability and yield reduces contamination risks, and produces high-quality cells for clinical use.
For instance, in September 2024, 10x Genomics, Inc. launched Chromium Xo, a new single cell instrument designed for researchers seeking high-quality data on limited budgets. This affordable entry point into routine, high-performance single cell analysis is part of its fleet of Chromium single cell instruments.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to rising cancer incidence, increased government funding, research on stem cell therapies, and increased awareness of advanced treatment methods.
For instance, in October 2024, Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, with a new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies.
Moreover, in August 2024, Pluri Inc has been granted a US patent for a new method for expanding immune cells using proprietary 3D cell expansion technology. This technology mimics the natural lymph node-like environment of immune cells within the human body, providing cells with the necessary conditions for efficient expansion at scale and quality.
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific, Inc, Merck KGaA, Becton, Dickinson and Company, GE Healthcare, Terumo BCT, Beckman Coulter Inc, Miltenyi Biotec, Stemcell Technologies, Inc., Takara Bio Inc., Lnza Group LTD among others.
Key Developments
- March 2026: Thermo Fisher Scientific expanded its Gibco cell culture portfolio with advanced media solutions to enhance scalability and efficiency in cell therapy manufacturing.
- February 2026: Sartorius AG invested in next-generation bioreactor technologies to support large-scale cell expansion for regenerative medicine and biologics production.
- January 2026: Lonza Group strengthened its cell & gene therapy capabilities by expanding GMP manufacturing capacity for clinical and commercial-scale cell expansion.
- December 2025: Cytiva introduced enhanced Xcellerex bioreactor systems with automation features for improved cell growth control and process consistency.
- November 2025: Merck KGaA advanced its cell culture media and single-use technologies, supporting efficient and contamination-free cell expansion workflows.
Why Purchase the Report?
- To visualize the global cell expansion market segmentation based on product type, cell type, application, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the cell expansion market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global cell expansion market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
